Sinaptica Therapeutics
@SinapticaTX
Followers
70
Following
7
Statuses
108
Revolutionizing the Treatment of Alzheimer’s Disease
Cambridge, MA
Joined October 2022
Positive 52-week Alzheimer's data presented today at #CTAD2024: Our personalized #neuromodulation therapy met primary and key secondary endpoints, showing strong statistical significance in mild-to-moderate patients, with no serious side-effects.
1
1
4
Phenomenal event leading into #JPM2025 in Jan. when our CEO Ken Mariash joined expert co-panelists for the Sachs Associates Neuroscience Innovation Forum #Sachs_NIF. Great to discuss #neurotech progress on the heels of our positive 52-wk data in #Alzheimers. #medtech #braincare
0
0
0
This holiday season, we reflect on all of the patients, families and caregivers living with #Alzheimers disease. Wishing all happy holidays full of memories, old and new. #ENDALZ #HappyHolidays
0
0
0
Healthcare Brew followed their earlier #neurotech feature with another article on recent progress in neurotechnology clincial trials, including Sinaptica, in coverage of #neuromodulation for #Alzheimers.
0
0
0
#TBTuesday In #Newsweek’s "New Era of Life Sciences" feature section on #Alzheimers, we shared our “patented new Alzheimer's treatment based on precision non-invasive brain stimulation, a painless treatment with virtually no side effects.” #ENDALZ
0
0
0
Check out this industry resource review article on non-invasive brain stimulation as a therapeutic for cognitive impairment and #Alzheimers in the Dec issue of the journal Brain by our scientific co-founders and Scientific Advisory Board member.
0
0
0
Healthcare Brew features Sinaptica in this in-depth look at the renaissance in #neurotech therapies for #Alzheimers and other diseases. #neuromodulation #BrainHealth #HealthTech #connectomics, #personalizedmedicine #neuroscience Full article here:
0
0
0
Congratulations to our scientific co-founder Emiliano Santarnecchi PhD, PhD, who was honored as a #DistinguishedInvestigator at the Academy for Biological & Medical Imaging Research meeting #RSNA24 in Chicago last week. #innovator #neuromodulation #neurotech
Join us in congratulating four of our 2024 #DistinguishedInvestigators 🏅. These Investigators will be honored at a ceremony and celebration at #RSNA24 in Chicago. For more program details, visit
0
0
1
MedPage Today followed up on their article on Giacomo Koch’s 52-week podium presentation at CTAD with a video interview digging into the positive results in Mild-to-Moderate #Alzheimers. #neuromodulation #ENDALZ See the video here:
0
0
0
As we move into the holiday season, we’re grateful for the opportunity to share precious memories and make new ones with family and friends. For so many affected by #Alzheimer’s disease, we realize each and every memory is a precious gift. Sending strength and support. #ENDALZ
0
0
1
Kudos to scientific co-founder Giacomo Koch MD, PhD, global #neuromodulation expert and lead author of this review in Brain of non-invasive brain stim, with co-authors scientific co-founder Emiliano Santarnecchi, PhD, PhD and Scientific Advisory Board member Giovanni Frisoni, MD.
Koch et al. review new approaches using non-invasive brain stimulation to try to enhance cognitive function or slow cognitive decline in patients with Alzheimer’s disease.
0
0
1
RT @Brain1878: Koch et al. review new approaches using non-invasive brain stimulation to try to enhance cognitive function or slow cognitiv…
0
55
0
Read this in-depth article in Medscape on our positive 52-week #Alzheimers data with our precision #neuromodulation therapy in Mild-to-Moderate patients at #CTAD2024. Full article here:
0
0
0
We made waves at #CTAD2024 after our podium presentation. The #Alzheimers community got to see first-hand our positive clinical results with an emerging safe, non-invasive, personalized #neuromodulation therapy. We’re excited for our company, the field and patients! #MedTech
0
0
1
We sat down with @neurology_live at #CTAD2024 to discuss our positive 52-week data in #Alzheimers with #neuromodulation, which met all endpoints across all 3 clinically measured domains – cognition, function, and behavior. #MedTech Full interview here:
0
1
1
This is a great overview of our positive 52-week data in Mild-to-Moderate #Alzheimers patients at #CTAD2024 by @_BrightFocus Foundation, supporter of the study. #neurotech #innovation #MedTech #AlzMoonshot #ENDALZ Read it here:
0
1
1
In great company at #CTAD2024 – #Alzheimers expert and Sinaptica SAB member Giovanni Frisoni, MD, pictured with Sinaptica scientific co-founder Giacomo Koch, after our presentation of positive 52-week data with #neuromodulation for Alzheimer’s. #neurotech #MedTech #ENDALZ
0
0
1
RT @startuphealth: 📢 @SinapticaTX, a member of our #AlzMoonshot, has announced significant results from their year-long clinical trial. We…
0
1
0
Additional coverage of our positive #Alzheimers data at #CTAD2024, on @YahooFinance Finance from Medical Device Network:
0
0
1
Stay tuned for our video interview at #CTAD2024 on @neurology_live!
Also this afternoon, we spoke with @SinapticaTX's Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD, who talked about 12-month data from a phase 2 study of non-invasive personalized neuromodulation treatment in patients with #Alzheimers. #CTAD24 @CTADconference
0
0
1